Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

In a recent conversation with Managed Healthcare Executive, Hunter shared reflections on his tenure, the challenges of expanding impact through partnerships and what he believes sets CareOregon apart from typical insurance organizations.

Results published in Blood suggest that Jakafi (ruxolitinib) might be used on a preventive basis. A trial comparing Jakafi to posttransplant cyclophosphamide is underway.

State efforts are aiming to bring more disclosure and transparency to PBM practices, mandating certain pharmacy reimbursement levels, requiring 100% pass-through rebates, and prohibiting spread pricing.

Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S. market in the third quarter of 2025. International rollouts are expected to follow.

This number can be attributed to claim denials, high deductibles and the underutilization of digital tools available within plans, according to the 2025 U.S. Commercial Member Health Plan Study from J.D. Power.

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain metastases, and improved quality of life in patients with advanced ALK-positive lung cancer.

Pharmacy costs and outpatient facility care generate 69% of the cost increase for 2025, according to Milliman’s recent Medical Index.

Jason R. Smith, Pharm.D., appointed as chief pharmacy officer in February 2025 for the University of Rochester Medical Center, talks about building a stronger workforce, managing drug shortages and keeping up with changes in regulations because of the new administration.

Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.

Researchers found that nearly 28% of hospitalized chronic liver disease patients with acute kidney injury had alcohol-related disorders, as did almost 60% with hepatorenal syndrome.

Sibeprenlimab would be offered in a prefilled syringe for subcutaneous injection. The PDUFA target action date is Nov. 28, 2025.

Scientists working at the NIH’s BRAIN Initiative have created new viral vectors that one day could lead to gene therapies for ALS, seizure disorders, Parkinson’s and Alzheimer’s disease, Huntington’s disease and other diseases of the brain.

Led by the University of Queensland’s research facility, Frazer Institute, the trial examining the drug ASITI-201 is the first of its kind in the world and has already dosed its first five participants.

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

Developed by Sarepta Therapeutics, Elevidys is a one-time, intravenous treatment that uses adeno-associated virus (AAV) technology to deliver a gene designed to produce a shortened form of the dystrophin protein, known as Elevidys micro-dystrophin, directly to skeletal muscle.

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ranibizumab, is delivered through an ocular implant that is refilled every nine months.

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Patients diagnosed with acquired (autoimmune) hemophilia, a serious and rare bleeding disorder, have high rates of hospital readmissions because of infections and bleeding, as well as high death rates especially among older patients.

Eric C. Hunter, president and CEO of CareOregon, spoke with Managed Healthcare Executive about the state’s innovative programs and the risks posed by uncertain federal funding.

Value-based healthcare programs are mostly used in rich countries and usually only in small parts of health systems. According to a study published in JAMA Health Forum, these tools can be harder to implement because of system problems, not enough long-term information and lack of research in low-income countries.

A case analysis provides a new understanding of the ocular side effects of Blenrep, an antibody drug conjugate that is being reviewed by the FDA as a combination treatment for patients with multiple myeloma. The goal date is July 23, 2025.

Respondents see the glucagon-like peptide 1 (GLP-1) drugs as a major advance. They also have concerns about whether insurers can afford to cover them and about wasteful prescriptions.

Nearly two-thirds expect to see delays related to staffing cuts at the FDA.